Fentanyl

Generic Name: Fentanyl

Brand Names: Abstral, Actiq, Duragesic, Effentora, Fentora, Instanyl, Lazanda, Sublimaze, Subsys, PecFent

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₈N_₂O

CAS Number: 437-38-7

Unique Ingredient Identifier: UF599785JZ

Background: Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia. Fentanyl is related to other opioids like morphine and oxycodone.

Fentanyl's high potency has also made it a common adulterant in illicit drugs, especially heroin. In 2017, 47600 overdose deaths in the United States involved some opioid (over 2/3 of all overdose deaths). Opioid overdoses kill an average of 11 Canadians daily.

Fentanyl was FDA approved in 1968.

Indication: Fentanyl intravenous or intramuscular injections are indicated for short term analgesia during induction, maintenance, and recovery from general or regional anesthesia. These injections are also used with a neuroleptic for premedication, induction, and as an adjunct to maintenance of anesthesia. Finally, fentanyl intravenous or intramuscular injections are used with oxygen for anesthesia in high risk patients.

Fentanyl sublingual tablets, transmucosal lozenges, buccal tablets, sublingual sprays, transdermal systems, and nasal sprays are indicated for the management of breakthrough pain in opioid tolerant cancer patients who require around the clock pain management.

Associated Conditions: Cancer Related Pain (Breakthrough Pain), Severe, Chronic Pain

Associated Therapies: Anesthetic premedication therapy, Anesthetics Agent, General Anesthesia, Induction of anesthesia therapy, Maintenance of anesthesia therapy, Regional Anesthesia therapy

Clinical Trials

Decrease Emergence Agitation and Provide Pain Relief for Children Undergoing Tonsillectomy & Adenoidectomy

Phase 3

Completed

Conditions: Obstructive Sleep Apnea

Interventions: Drug: fentanyl
Drug: dexmedetomidine

First Posted Date: 2007-05-01

Last Posted Date: 2016-12-05

Lead Sponsor: University of Medicine and Dentistry of New Jersey

Target Recruit Count: 122

Registration Number: NCT00468052

Locations: 🇺🇸
UMDNJ University Hospital, Newark, New Jersey, United States

Preventive Analgesia in Multiparas Undergoing Induction of Labour

Not Applicable

Completed

Conditions: Pain

Interventions: Drug: bupivacaine, fentanyl
Drug: preservative free saline

First Posted Date: 2007-04-24

Last Posted Date: 2007-12-17

Lead Sponsor: Samuel Lunenfeld Research Institute, Mount Sinai Hospital

Target Recruit Count: 16

Registration Number: NCT00465231

Locations: 🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada

Efficacy and Safety of Fentanyl Buccal Tablets Compared With Oxycodone for the Management of Break Through Pain

Phase 3

Completed

Conditions: Chronic Pain

Interventions: Drug: Fentanyl Buccal Tablets Compared With Immediate-Release Oxycodone

First Posted Date: 2007-04-19

Last Posted Date: 2012-05-28

Lead Sponsor: Cephalon

Target Recruit Count: 323

Registration Number: NCT00463047

Locations: 🇺🇸
Center for Prospective Outcome Studies, Inc., Atlanta, Georgia, United States
🇺🇸
Columbus Clinical Research, Columbus, Ohio, United States
🇺🇸
Willis-Knighton Pain Management Center, Shreveport, Louisiana, United States

and more 40 locations

Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids

Phase 3

Completed

Conditions: Cancer Pain

Interventions: Drug: Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)

First Posted Date: 2007-04-11

Last Posted Date: 2012-01-25

Lead Sponsor: Archimedes Development Ltd

Target Recruit Count: 73

Registration Number: NCT00459277

Locations: 🇺🇸
Beth Israel Medical Center, New York, New York, United States

Long Term Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain

Phase 3

Completed

Conditions: Cancers, Pain

Interventions: Drug: Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)

First Posted Date: 2007-04-11

Last Posted Date: 2013-07-11

Lead Sponsor: Archimedes Development Ltd

Target Recruit Count: 403

Registration Number: NCT00458510

Cognitive Impairment Following Sedation for Colonoscopy With Propofol, Midazolam and Fentanyl Combinations

Phase 4

Completed

Conditions: Cognitive Impairment

Interventions: Drug: Propofol, midazolam, fentanyl

First Posted Date: 2007-03-12

Last Posted Date: 2013-05-30

Lead Sponsor: Melbourne Health

Target Recruit Count: 200

Registration Number: NCT00446420

Locations: 🇦🇺
Royal Melbourne Hospital, Parkville, Victoria, Australia

Neuronal Mechanisms of Sensory Processing During General Anesthesia

Not Applicable

Conditions: General Anesthesia

First Posted Date: 2007-02-13

Last Posted Date: 2010-07-30

Lead Sponsor: Ludwig-Maximilians - University of Munich

Target Recruit Count: 768

Registration Number: NCT00434382

Locations: 🇩🇪
Klinik fuer Anaesthesiologie am Universitätsklinikum Schleswig Holstein, Campus Luebeck, Lubeck, Germany
🇩🇪
Klinik fuer Anaesthesiologie der Ludwigs-Maximilians-Universitaet Muenchen, Munich, Germany
🇩🇪
Krankenhaus Friedrichshafen, Friedrichshafen, Germany

and more 1 locations